期刊文献+

莫西沙星治疗老年中-重度下呼吸道感染的临床观察 被引量:8

暂未订购
导出
摘要 目的 评价莫西沙星注射液治疗老年中.重度下呼吸道感染的临床应用价值。方法 采用随机对照设计,将62例中.重度呼吸道感染老年患者分为两组:治疗组30例,给予莫西沙星注射液400nag静脉滴注,每日1次,疗程7~14d;对照组32例,给予头孢哌酮/舒巴坦纳2.0g,每日2次,疗程7~14d。结果 治疗组临床治愈率为83.3%(25/30),有效率为93.3%(28/30),细菌清除率为92.3%(12/13)。而对照组分别为81.3%(26/32)。93.8%(30/32)和92.9%(13/14)。经统计学处理两组差异无显著性。两组不良反应发生率分别为6.7%和9.4%。结论 莫西沙星可作为经验性治疗老年中一重度下呼吸道感染适宜选用的药物,是一种高效、广谱、安全的新型抗菌药。
出处 《中国老年学杂志》 CAS CSCD 北大核心 2007年第18期1786-1788,共3页 Chinese Journal of Gerontology
  • 相关文献

参考文献7

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2Dovem GV.Antimicrobial use and the emergence of antimicrobial resistance with streptococcus pneumoniae in the United States[J].Clin Infect.Dis,2001;33(3):S187-92.
  • 3Dolhoff A,Petenen U.Endermann R.In vitro activity of BAY 12-8039,a new 8-methoxyquinolone[J].J Chemotherapy,1996;42:410-25.
  • 4Hansen GT.Metzler K.Drlica K,et al.Mutant prevention concentration of gemifloxacin for clinical isolates of streptococcus pneumoniae[J].Antimicrob Agents Chemother,2003;47:440-l.
  • 5Soman A,Honeybojme O.Andrews J,et al.Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibreoptic bronchoscopy[J].J Antimicrob Chemother,1999;44:835-8.
  • 6Piddock LJ.Mechanisms of floroquinolone resistance:an update 1994-1998[J].Drugs,1999;58(2):S11-8.
  • 7张文辉,朱述阳,陈昊,张志亮,张业清,邵华军.莫西沙星注射液治疗中-重度社区获得性肺炎疗效观察[J].中国感染与化疗杂志,2006,6(5):296-300. 被引量:16

二级参考文献23

  • 1沈定霞,罗燕萍,崔岩,赵莉萍,白立彦.分离产金属β-内酰胺酶的铜绿假单胞菌[J].中华医院感染学杂志,2004,14(1):86-88. 被引量:109
  • 2[4]Hirakata Y, Izumikawa K, Yamaguchi K, et al.Rapid detection and evolution of clinical characteristics of emerging multiple-drug-resistant Gram-negative rods carrying the metallo-β-lactamase gene blaIMP[J]. Antimicrob Agents Chemother, 1998, 42: 2006-2011.
  • 3[5]Arakawa Y, Shibata N, Shibayama K, et al. Convenient test for screening metallo-β-lactamase-producing Gram-negative bacteria by using thiol compounds[J]. J Clin Microbiol, 2000, 38(1): 40-43.
  • 4[6]National Committee for Clinical Laboratory Standards. Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard[S]. Fifth edition. Wayne Pennsylvania National Committee for Clinical Laboratory Standards. 2001.
  • 5[7]Saino Y, Kobayash F, Inoue M, et al. Purification and properties of inducible penicillin-beta-lactamase isolates from Pseudomonas maltophilia[J]. Antimicrob Agents Chemother, 1982, 22: 564-570.
  • 6[8]Senda K, Arakawa Y, Nakashima K, et al. Multifocal outbreaks of metallo-β-lactamase-producing Pseudomonas aeruginosa resistant to broad-spectrum β-lactams, including carbapenems[J]. Antimicrob Agents Chemother, 1996, 40(2): 349-353.
  • 7Dovern GV.Antimicrobial use and the emergence of antimicrobial resistance with streptococcus pneumoniae in the United States[J].Clin Infect Dis,2001,33(suppl 3):S187-192.
  • 8Dolhoff A,Petersen U,Endermann R.In vitro activity of BAY 12-8039,a new 8-methoxyquinolo[J].Chemotherapy,1996,42:410-425.
  • 9Andrews JM,Honeybourne D,Jevons G,et al.Concentrations of levofloxacin (HR 355) in the respiratory tract following a single oral dose in patients undergoing fibre optic bronchoscopy[J].J Antimicrob Chemother,1997,40:573-577.
  • 10Soman A,Honeybourne D,Andrews J,et al.Concentrations of moxifloxacin in serum and pulmonary compartments following a single 400 mg oral dose in patients undergoing fibre-optic bronchoscopy[J].J Antimicrob Chemother,1999,44:835-838.

共引文献123

同被引文献53

引证文献8

二级引证文献48

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部